Correlation between metastatic potential and variants from colorectal tumor cell line HT-29
- PMID: 14606113
- PMCID: PMC4656557
- DOI: 10.3748/wjg.v9.i11.2627
Correlation between metastatic potential and variants from colorectal tumor cell line HT-29
Abstract
Aim: To evaluate the relationship between uPA, PAI-1, CEA, PI3K and metastatic potential in three colorectal tumor cell lines.
Methods: Metastatic model in nude rats was established by variants HT-29c and HT-29d cell lines and the metastatic potential of two tumor cell variants was compared. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) were determined using ELISA in colorectal carcinoma WiDr, HT-29 and HT-29d cell lines with different metastatic potentials. Expression of carcinoembryonic antigen (CEA) and phosphoinositide 3-kinase (PI3-Kinase) was analyzed using immunohistochemistry (IHC) in these cell lines in vitro and in vivo. CEA expression was compared using fluorescence activated cell sorter (FACS) in vitro.
Results: The number of HT-29d cells arrested in liver dramatically decreased within the initial 24 hours after injection. The taking rate of liver metastases in the variant HT-29d increased as compared with parental HT-29 cells (70% versus 50%) and a variant HT-29b cells (70% versus 60%), and extensive organs were synchronously involved in metastases. The uPA concentration of variant HT-29d cell line was significantly higher than that of the non-metastatic WiDr and the low metastatic HT-29 cell lines. The variant HT-29d cells produced stronger PI3-kinase expression as compared with the non-metastatic WiDr cells and the low metastatic HT-29 cells in vivo.
Conclusion: The selected variant HT-29d cell exhibited an enhanced metastatic potential. The level of uPA and PAI-1 is positively correlated with the metastatic capacity of tumor cells. The expression of PI3-kinase correlates with tumor development and metastasis.
Similar articles
-
[Comparative analysis of metastatic variants from the colorectal tumor cell line HT-29].Zhejiang Da Xue Xue Bao Yi Xue Ban. 2002 Aug;31(5):355-358. doi: 10.3785/j.issn.1008-9292.2002.05.011. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2002. PMID: 12601885 Chinese.
-
The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.Gen Diagn Pathol. 1995 May;141(1):41-8. Gen Diagn Pathol. 1995. PMID: 8542506
-
Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.Gynecol Oncol. 2007 Feb;104(2):470-9. doi: 10.1016/j.ygyno.2006.08.048. Epub 2006 Oct 30. Gynecol Oncol. 2007. PMID: 17070899 Free PMC article.
-
Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?Eur J Surg Oncol. 2017 Feb;43(2):252-257. doi: 10.1016/j.ejso.2016.06.002. Epub 2016 Jun 20. Eur J Surg Oncol. 2017. PMID: 27345498 Review.
-
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.Thromb Haemost. 2004 Mar;91(3):450-6. doi: 10.1160/TH03-12-0798. Thromb Haemost. 2004. PMID: 14983219 Review.
Cited by
-
Metastatic tumor cell arrest in the liver-lumen occlusion and specific adhesion are not exclusive.Int J Colorectal Dis. 2009 Jul;24(7):851-8. doi: 10.1007/s00384-009-0694-2. Epub 2009 Mar 25. Int J Colorectal Dis. 2009. PMID: 19319542
-
MicroRNA-5p and -3p co-expression and cross-targeting in colon cancer cells.J Biomed Sci. 2014 Oct 5;21(1):95. doi: 10.1186/s12929-014-0095-x. J Biomed Sci. 2014. PMID: 25287248 Free PMC article.
-
Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells.BMC Cancer. 2015 Dec 16;15:975. doi: 10.1186/s12885-015-1950-1. BMC Cancer. 2015. PMID: 26673628 Free PMC article.
-
CEACAM1 modulates epidermal growth factor receptor--mediated cell proliferation.J Clin Invest. 2004 Oct;114(7):944-52. doi: 10.1172/JCI21786. J Clin Invest. 2004. PMID: 15467833 Free PMC article.
-
Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells.Mol Imaging Biol. 2005 Nov-Dec;7(6):388-92. doi: 10.1007/s11307-005-0011-6. Mol Imaging Biol. 2005. PMID: 16284704
References
-
- Schmitt M, Wilhelm O, Jänicke F, Magdolen V, Reuning U, Ohi H, Moniwa N, Kobayashi H, Weidle U, Graeff H. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): A new target in tumor invasion and metastasis. J Obstet Gynaecol ( Tokyo 1995) 1995;21:151–165. - PubMed
-
- Gershtein ES, Kushlinskii NE. Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors. Bull Exp Biol Med. 2001;131:67–72. - PubMed
-
- Yamamoto M, Ueno Y, Hayashi S, Fukushima T. The role of proteolysis in tumor invasiveness in glioblastoma and metastatic brain tumors. Anticancer Res. 2002;22:4265–4268. - PubMed
-
- Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer. 1997;79:878–883. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous